enGene Holdings Inc. Common Stock (ENGN) - Total Assets
Based on the latest financial reports, enGene Holdings Inc. Common Stock (ENGN) holds total assets worth $337.11 Million USD as of January 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ENGN net asset quality index to measure how much of total assets are equity-financed.
enGene Holdings Inc. Common Stock - Total Assets Trend (2021–2025)
This chart illustrates how enGene Holdings Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Explore enGene Holdings Inc. Common Stock strategic investment ratio to see how much of total assets are deployed in long-term investments.
enGene Holdings Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (October 2025)
enGene Holdings Inc. Common Stock's total assets of $337.11 Million consist of 90.9% current assets and 9.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.7% |
| Accounts Receivable | $2.23 Million | 1.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how enGene Holdings Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of enGene Holdings Inc. Common Stock.
Key Asset Composition Facts
- Current vs. Non-Current Assets: enGene Holdings Inc. Common Stock's current assets represent 90.9% of total assets in 2025, an increase from 1.2% in 2021.
- Cash Position: Cash and equivalents constituted 22.7% of total assets in 2025, up from 0.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 1.0% of total assets.
enGene Holdings Inc. Common Stock Competitors by Total Assets
Key competitors of enGene Holdings Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €8.68 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $452.70 Million |
|
Tourmaline Bio Inc.
NASDAQ:TRML
|
USA | $269.30 Million |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230
|
China | CN¥1.32 Billion |
enGene Holdings Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.75 | 17.16 | 4.79 |
| Quick Ratio | 11.75 | 17.16 | 4.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $264.61 Million | $209.37 Million | $1.24 Million |
enGene Holdings Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between enGene Holdings Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.40 |
| Latest Market Cap to Assets Ratio | 0.48 |
| Asset Growth Rate (YoY) | -28.8% |
| Total Assets | $221.47 Million |
| Market Capitalization | $106.51 Million USD |
Valuation Analysis
Below Book Valuation: The market values enGene Holdings Inc. Common Stock's assets below their book value (0.48x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: enGene Holdings Inc. Common Stock's assets decreased by 28.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for enGene Holdings Inc. Common Stock (2021–2025)
The table below shows the annual total assets of enGene Holdings Inc. Common Stock from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-10-31 | $221.47 Million | -28.83% |
| 2024-10-31 | $311.17 Million | +257.84% |
| 2023-10-31 | $86.96 Million | -34.14% |
| 2022-10-31 | $132.04 Million | +0.45% |
| 2021-10-31 | $131.45 Million | -- |
About enGene Holdings Inc. Common Stock
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. T… Read more